{"id":"a-pacritinib","phase":"phase_1","safety":{"commonSideEffects":[{"rate":"34%","effect":"Anemia"},{"rate":"32%","effect":"Thrombocytopenia"},{"rate":"29%","effect":"Neutropenia"}]},"status":"active","trials":["NCT02807207"],"aliases":["A: pacritinib 400mg"],"patents":[],"pricing":[],"timeline":[],"aiSummary":"JAK2 inhibitor Used for Myelofibrosis.","brandName":"A: pacritinib","companyId":"cti-biopharma","mechanism":{"_ai_source":"groq-llama-8b","explanation":"Pacritinib is a potent and selective inhibitor of the JAK2 enzyme, which plays a key role in the signaling pathways that regulate cell growth and survival.","oneSentence":"JAK2 inhibitor","_ai_confidence":"medium"},"commercial":null,"companyName":"CTI BioPharma","competitors":[],"genericName":"A: pacritinib","indications":{"approved":[{"name":"Myelofibrosis"}]},"labelChanges":[],"trialDetails":[],"manufacturing":[],"administration":{"icon":"","route":"","frequency":"","formulation":""},"formularyStatus":[],"apiManufacturers":[],"developmentCodes":[],"ownershipHistory":[],"biosimilarFilings":[],"firstApprovalDate":"","companionDiagnostics":[],"firstApprovalCountry":null,"rwe":[],"genericFilers":[],"relatedDrugs":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"modality":"Small molecule","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":false,"score":3}}